(Q37937858)

25 August 2017

1 reference

title

Clinical trials and decision-making strategies for optimal treatment of relapsed ovarian cancer (English)

1 reference

25 August 2017

1 reference

1 reference

Jonathan A Ledermann

1

1 reference

25 August 2017

Fharat A Raja

series ordinal

2

1 reference

25 August 2017

publication date

1 September 2011

1 reference

European Journal of Cancer

25 August 2017

published in

1 reference

25 August 2017

volume

47 Suppl 3

1 reference

25 August 2017

page(s)

S104-15

1 reference

Intraperitoneal cisplatin and paclitaxel in ovarian cancer.

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Treatment of relapsed carcinoma of the ovary with cisplatin or carboplatin following initial treatment with these compounds

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Prognostic factors for stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Review of phase II trial designs used in studies of molecular targeted agents: outcomes and predictors of success in phase III.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Optimising the design of phase II oncology trials: the importance of randomisation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Speeding up the evaluation of new agents in cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Early versus delayed treatment of relapsed ovarian cancer (MRC OV05/EORTC 55955): a randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Management of ovarian cancer: referral to a multidisciplinary team matters

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Quality of life evaluations in patients with ovarian cancer during chemotherapy treatment

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Second-line platinum therapy in patients with ovarian cancer previously treated with cisplatin

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Predictors of response to subsequent chemotherapy in platinum pretreated ovarian cancer: a multivariate analysis of 704 patients [seecomments]

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Guidelines and selection criteria for secondary cytoreductive surgery in patients with recurrent, platinum-sensitive epithelial ovarian carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Surgery in recurrent ovarian cancer: the Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Effective palliative radiotherapy for symptomatic recurrent or residual ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Rapid inpatient/outpatient desensitization for chemotherapy hypersensitivity: standard protocol effective in 57 patients for 255 courses

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Pegylated liposomal Doxorubicin and Carboplatin compared with Paclitaxel and Carboplatin for patients with platinum-sensitive ovarian cancer in late relapse

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Trabectedin plus pegylated liposomal Doxorubicin in recurrent ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Phase II study of liposomal doxorubicin in refractory ovarian cancer: antitumor activity and toxicity modification by liposomal encapsulation.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Phase 2 trial of single-agent gemcitabine in platinum-paclitaxel refractory ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Randomized phase III study of canfosfamide in combination with pegylated liposomal doxorubicin compared with pegylated liposomal doxorubicin alone in platinum-resistant ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Weekly cisplatin and daily oral etoposide is highly effective in platinum pretreated ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

A phase II trial of weekly paclitaxel and every 3 weeks of carboplatin in potentially platinum-sensitive ovarian and peritoneal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Experience in a UK cancer centre of weekly paclitaxel in the treatment of relapsed ovarian and primary peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Weekly carboplatin and paclitaxel is safe, active, and well tolerated in recurrent ovarian cancer cases of Japanese women previously treated with cisplatin-containing multidrug chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Antiestrogen therapy is active in selected ovarian cancer cases: the use of letrozole in estrogen receptor-positive patients

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Chemotherapy versus hormonal treatment in platinum- and paclitaxel-refractory ovarian cancer: a randomised trial of the German Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) Study Group Ovarian Cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Experience with bevacizumab in the management of epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Phase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group Study

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

What is the risk of bowel perforation associated with bevacizumab therapy in ovarian cancer?

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Randomized phase II placebo-controlled trial of maintenance therapy using the oral triple angiokinase inhibitor BIBF 1120 after chemotherapy for relapsed ovarian cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Folate receptor alpha as a tumor target in epithelial ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

A synthetic lethal therapeutic approach: poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Sporadic epithelial ovarian cancer: clinical relevance of BRCA1 inhibition in the DNA damage and repair pathway

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Ovarian carcinomas with genetic and epigenetic BRCA1 loss have distinct molecular abnormalities

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

Hallmarks of 'BRCAness' in sporadic cancers

1 reference

https://api.crossref.org/works/10.1016%2FS0959-8049%2811%2970154-X

7 January 2021

10.1016/S0959-8049(11)70154-X

Identifiers

DOI

1 reference

25 August 2017

1 reference